This site uses cookies. By using this site you agree to receiving cookies. View Policy.

This pitch is currently hidden from the wider Crowdcube community to give selected investors known to the business an early opportunity to invest. As such only users with the URL can view this pitch.
Capital at risk
LIFE LENGTH
  • Equity
  • Spain Spain
days left
8
13%
Raised
£88,050
Investors
24
Target
£650,000
Equity
1.85%
Pre-money valuation
£34,400,000

Life Length is the leading company in the field of telomere diagnostics and analyses worldwide. During the past two years, we have carried out major clinical studies for improved cancer diagnosis and prognosis. Now we plan to launch these services to improve patient care quality.

  • Since 2011 providing telomere testing services in over 35 countries
  • More than 6,000 samples collected in our oncology study
  • Developing a new diagnostic test in prostate cancer
  • Hundreds of thousands of unnecessary biopsies potentially spared

Idea

Over one million unnecessary prostate biopsies are performed yearly in healthy patients due to the lack of accurate screening tests. These biopsies are invasive, expensive and risky, with physical and emotional consequences.

There is an unmet medical need for new biomarkers for prostate cancer screening that can avoid these unnecessary biopsies. Worldwide stats show that about 65% of biopsied patients do not have cancer.

ProsTAV is our sophisticated prostate cancer risk score test that we have developed with our proprietary technology thanks to a clinical study involving 1,200 prostate biopsied patients. Combined with the current screening methodology, this simple blood test can save hundreds of thousands of men each year from unnecessary biopsies, surgeries and needless complications.

Our new test, less expensive and invasive than a biopsy, could save up to 50% of these unnecessary biopsies. It is huge market with an estimated 6 million cases worldwide. In the UK, it is one of the most frequently diagnosed cancers (over 50,000 annually).

We are the world leader in telomere measurement and we are now combining our Telomere Associated Variables with the current standard of care in cancer. Our technology is the only one commercially available in the world able to extract these variables.

THE MATERIALS YOU ARE SEEKING TO ACCESS ARE BEING MADE AVAILABLE BY THE COMPANY RAISING FINANCE AS IDENTIFIED ABOVE (THE "COMPANY") IN GOOD FAITH AND FOR INFORMATION PURPOSES ONLY AND SUBJECT TO THESE TERMS AND CONDITIONS.  CROWDCUBE CAPITAL LTD IS AUTHORISED BY THE FCA AND CARRIES OUT DUE DILIGENCE ON EACH COMPANY THAT LISTS ON CROWDCUBE AS SET OUT HERE.
 
This investment opportunity is not an offer to the public and is only available to registered members of Crowdcube.com who have qualified and categorised themselves as able to invest.  The investment opportunity is not directed at persons located in the United States, Canada or Japan. Any person resident outside the United Kingdom who wishes to view these materials must first satisfy themselves that they are not subject to any local requirements that prohibit or restrict access.
In particular, unless otherwise determined by the Company and permitted by applicable law and regulation, it is not intended, subject to certain exceptions, that any offering of the securities mentioned in such materials (the "Securities") by the Company would be made, or any documentation be sent in or into, the United States, Canada or Japan.  There will be no public offering of the Securities in the United States.
 
In order to access the pitch you must first become a qualifying member of Crowdcube on the basis of your status as either (i) self-certified ‘high net worth investor’, (ii) certified ‘sophisticated investor’, (iii) self-certified as a ‘sophisticated investor’ or (iv) certified as a ‘restricted investor’, in each case in accordance with the FCA’s Conduct of Business Sourcebook Chapter 4.7.  Potential investors are encouraged to "cross examine" the Company by interactive due diligence and use of the available online forums to bring the "wisdom of the crowd" to bear.  Accessing the pitch also means you agree to Crowdcube’s most recent website terms and conditions and investor terms and conditions, which include Crowdcube's limitation of liability.
 
If you are not permitted to view materials on this webpage or are in any doubt as to whether you are permitted to view these materials, please exit this webpage.  Crowdcube’s or the Issuer’s press announcements and this information page do not constitute an offer to sell securities of the Company.  Further, it does not constitute a recommendation by the Company, Crowdcube or any other party to sell or buy securities in the Company.
 
By registering or logging into Crowdcube.com to view the investment opportunity, you certify that you are legally entitled to view the investment opportunities, are an authorised investor and you agree to all applicable terms and conditions on this website, including this disclaimer.

To see the rest of the LIFE LENGTH pitch, join now.
It’s free, quick and easy.

Join

Already registered? Log in

To see the rest of the LIFE LENGTH pitch, join now.
It’s free, quick and easy.

LIFE LENGTH

Join to read more information about the LIFE LENGTH team, documents, and what other investors are saying about the pitch.

If you choose to invest we won’t take your money until the pitch closes and you can cancel your investment at any time.

Crowdcube is a leading investment crowdfunding platform

Successfully Invested
£689m+
Registered Investors
751k+